Your new post is loading...
|
Scooped by
Sergio Ariño Blasco
December 3, 7:07 AM
|
AbstractBackground. Metabolomic scores based on age (MetaboAge) and mortality (MetaboHealth) are considered indicators of overall health, but their associa
|
Scooped by
Sergio Ariño Blasco
December 3, 7:03 AM
|
AbstractBackground. The application of clinical practice guidelines (CPGs) across the spectrum of individuals living with diabetes can be challenging, part
|
Scooped by
Sergio Ariño Blasco
December 3, 7:01 AM
|
Abstract. Behavioural symptoms are common manifestations of Parkinson’s disease (PD). Early behavioural symptoms characterise mild behavioural impairment (
|
Scooped by
Sergio Ariño Blasco
December 3, 6:34 AM
|
|
Scooped by
Sergio Ariño Blasco
December 3, 6:24 AM
|
Early DOAC initiation within 4 days after ischaemic stroke associated with atrial fibrillation was non-inferior to delayed initiation for the composite outcome of ischaemic stroke, intracranial haemorrhage, unclassifiable stroke, or systemic embolism at 90 days. Our findings do not support the current common and guideline-supported practice of delaying DOAC initiation after ischaemic stroke with atrial fibrillation.
|
Scooped by
Sergio Ariño Blasco
December 3, 6:17 AM
|
In most countries, especially in low-income and middle-income countries, diabetes treatment has not increased at all or has not increased sufficiently in comparison with the rise in prevalence. The burden of diabetes and untreated diabetes is increasingly borne by low-income and middle-income countries. The expansion of health insurance and primary health care should be accompanied with diabetes programmes that realign and resource health services to enhance the early detection and effective treatment of diabetes.
|
Scooped by
Sergio Ariño Blasco
December 3, 6:15 AM
|
With the advent of the first disease-modifying, anti-amyloid β-directed passive immunotherapy for Alzheimer's disease, questions arise who, when, and how to treat. This paper describes shortly the pathogenic basis of and preclinical data, which have, more than two decades ago, initiated the development of this vaccination therapy. We discuss clinical trial results of aducanumab, lecanemab, and donanemab. We also review appropriate use recommendations of these novel treatments on patient selection and safety monitoring.
|
Scooped by
Sergio Ariño Blasco
December 3, 6:06 AM
|
In contrast to a mere 5 years ago, discussions about menopause are now more mainstream, with the 2024 Super Bowl advertisement for a drug to treat hot flashes and night sweats related to menopause being a recent example. The drug being advertised, fezolinetant, was the first novel dru
|
Scooped by
Sergio Ariño Blasco
October 16, 2:09 AM
|
This is a transformative time for patients with Alzheimer disease. Alzheimer disease is increasingly viewed as a treatable condition and managed like other major chronic diseases, such as heart disease and cancer. Management of Alzheimer disease includes early diagnosis with molecula
|
Scooped by
Sergio Ariño Blasco
October 16, 2:03 AM
|
This prospective study evaluates a clinically available Alzheimer disease blood test in primary and secondary care using predefined biomarker cutoff values.
|
Scooped by
Sergio Ariño Blasco
October 13, 1:58 AM
|
Objectives: To determine whether a Frailty Index based on laboratory tests (FI-lab) is associated with clinical outcomes independently of a standard nonlaboratory Frailty Index (FI-clinical) in older patients starting home-based medical care. Conclusions and Implications: FI-lab was associated with 2-year mortality in patients starting home-based medical care, independently of FI-clinical, and may be useful for risk assessment in this population. Studies with larger sample sizes are needed.
|
Scooped by
Sergio Ariño Blasco
October 9, 8:05 AM
|
This special article emphasizes the complex interplay between specific fracture types, their management options, and the roles of comorbidity and polypharmacy, highlighting the essential role of orthogeriatricians. Orthogeriatricians navigate the complexities posed by comorbidities, frailty, and polypharmacy, significantly influencing treatment outcomes
|
Scooped by
Sergio Ariño Blasco
October 9, 7:52 AM
|
Background: Older adults attending the Emergency Department (ED) should be assessed using a frailty screening tool as older adults living with frailty are more likely to experience adverse outcomes. The Clinical Frailty Scale (CFS) is commonly used for this. This systematic review and meta-analysis synthesise the literature studying predictive accuracy of the CFS for identifying older adults at risk of adverse outcomes following ED visit, and the diagnostic accuracy of the CFS for identifying older adults living with frailty attending the ED. Conclusion: The CFS successfully identifies those at risk of adverse outcomes of death, ED revisit, hospitalisation and institutionalisation. However, there is a paucity of studies which assess its diagnostic accuracy. Overall, it is a useful screening tool to identify those who may benefit from comprehensive multidisciplinary assessment in the ED setting.
|
|
Scooped by
Sergio Ariño Blasco
December 3, 7:04 AM
|
AbstractIntroduction. Approximately 2 million people in Italy are currently living with dementia or mild cognitive impairment (MCI), and 4 million are invo
|
Scooped by
Sergio Ariño Blasco
December 3, 7:02 AM
|
AbstractBackground. Frailty is of increasing interest in trials, either as a target of intervention, as an outcome or as a potential treatment modifier. Ho
|
Scooped by
Sergio Ariño Blasco
December 3, 6:35 AM
|
|
Scooped by
Sergio Ariño Blasco
December 3, 6:31 AM
|
|
Scooped by
Sergio Ariño Blasco
December 3, 6:22 AM
|
Nearly 80 years after the end of the National Socialist (Nazi) regime, its legacies persist with the continued use of anatomical atlases whose precise origins remain unknown.1 Although previous investigations on the history of anatomy during the Nazi era have revealed unsettling evidence concerning the Pernkopf atlas and other publications of knowledge gained from the bodies of Nazi victims in life and death,2 there remains poor insight into the origins of other anatomical atlases of this period.
|
Scooped by
Sergio Ariño Blasco
December 3, 6:16 AM
|
Almost 40 000 people died alone at home in Japan this year—many unnoticed for months—prompting much concern, and new policy. Megan Tatum reports.
|
Scooped by
Sergio Ariño Blasco
December 3, 6:13 AM
|
This review summarizes current evidence on recommended treatments for acute pericarditis, its prognosis, and the diagnostic evaluation of individuals with suspected initial or recurrent pericarditis.
|
Scooped by
Sergio Ariño Blasco
October 16, 2:11 AM
|
This Review summarizes current evidence on pathogenesis, epidemiology, diagnosis, and treatment of community-acquired pneumonia and focuses on adults without immune-compromising conditions.
|
Scooped by
Sergio Ariño Blasco
October 16, 2:08 AM
|
This cohort study characterizes temporal changes in plasma biomarkers, identifies factors associated with changes in plasma biomarkers over time, and evaluates the prospective associations of plasma biomarkers with late-life all-cause dementia.
|
Scooped by
Sergio Ariño Blasco
October 13, 2:00 AM
|
Objective: Intrinsic capacity (IC) and frailty are complementary constructs that encapsulate functional capacities of older adults. Although earlier studies suggest the utility of composite IC scores in predicting risk of frailty, key gaps remain with the lack of direct comparative studies between different IC scales and lack of a composite score based on the World Health Organization Integrated Care for Older People (ICOPE) tool.We aimed to compare different IC scales, including an ICOPE-based scale, in their predictive ability for risk of frailty at 2 years in healthy community-dwelling older adults. Conclusions and Implications: Baseline composite IC score using 2-point per domain scales better predicted risk of frailty at 2 years, predicated on impaired locomotion/vitality and greater number of impaired domains. For early identification of healthy older adults at risk of frailty, an ICOPE-based scale should be considered, as it is effective and accessible.
|
Scooped by
Sergio Ariño Blasco
October 9, 8:06 AM
|
Alzheimer’s disease (AD) is a prevalent neurodegenerative disease characterized by progressive cognitive and functional decline. Nearly all patients with AD develop neuropsychiatric symptoms (NPSs). Agitation is one of the most distressing and challenging NPS. Brexpiprazole is an oral antipsychotic and is the first approved pharmacologic agent in the United States for the treatment of agitation associated with dementia due to AD. Its effect is thought to be from its partial serotonin 5-HT1A and dopamine D2 receptor agonist activity and serotonin 5-HT2A receptor antagonism. Brexpiprazole is a maintenance medication, and it should not be used “as needed” or as a “PRN” treatment for breakthrough agitation. Brexpiprazole is a major substrate of CYP2D6 and CYP3A4. Dose adjustments may be required for drug interactions or impaired renal or hepatic function. Clinical trials found brexpiprazole 2 to 3 mg/d demonstrated significant improvements in agitation, with brexpiprazole showing an approximate 5-point greater reduction on change in the Cohen-Mansfield Agitation Inventory total score at week 12 from baseline compared with placebo. Brexpiprazole is generally well tolerated and safe, and common adverse reactions when used for this indication include dizziness, headaches, insomnia, nasopharyngitis, somnolence, and urinary tract infections. Like other antipsychotics used for agitation in AD, brexpiprazole is associated with higher mortality rates compared with placebo. In a long-term care setting, there are several considerations for its use. Benefits include an oral agent that is well tolerated and clinical data showing statistically significant effects on agitation. However, brexpiprazole has not been studied in head-to-head clinical trials against other antipsychotics, and there are differing opinions if the agitation score reductions translate to a clinically meaningful difference. The approval of brexpiprazole signals favorably for upcoming agents for this indication, including escitalopram and dextromethorphan-bupropion. Both escitalopram and dextromethorphan-bupropion are currently undergoing clinical trials.
|
Scooped by
Sergio Ariño Blasco
October 9, 7:56 AM
|
Objectives: Loneliness and social isolation are associated with adverse health outcomes, especially within the older adult population, underlining the need for effective interventions. This systematic review and metaanalysis aims to summarize all available evidence regarding the effectiveness of interventions for loneliness and social isolation, to map out their working mechanisms, and to give implications for policy and practice. Conclusions and Implications: Interventions for loneliness and social isolation can generally be effective, although some unexplained between-study heterogeneity remains. Further research is needed regarding the applicability of interventions across different settings and countries, also considering their cost-effectiveness
|